DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,308,234 B2 Arnold Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,308,234 B2 Arnold Et Al USOO93O8234B2 (12) United States Patent (10) Patent No.: US 9,308,234 B2 Arnold et al. (45) Date of Patent: Apr. 12, 2016 (54) METHODS AND COMPOSITIONS FOR (56) References Cited TREATING MIUCOSAL TISSUE DISORDERS U.S. PATENT DOCUMENTS (71) Applicant: The University of North Carolina at 2,606,903. A 8, 1952 Ruskin Chapel Hill, Chapel Hill, NC (US) 2,822.317 A 2f1958 Gulesich et al. 4.324,778 A 4, 1982 Davis 4,578,390 A 3, 1986 Jensen et al. (72) Inventors: Roland R. Arnold, Chapel Hill, NC 4,617, 187 A 10/1986 Okuyama et al. (US); David C. Henke, Chapel Hill, NC 4,670471 A 6, 1987 Clark (US) 4,686,235 A 8/1987 Chang et al. 4,707,354 A 11/1987 Garlen et al. 4,822,816 A 4, 1989 Markham (73) Assignee: The University of North Carolina at 4,861,783 A 8, 1989 Ackerman et al. Chapel Hill, Chapel Hill, NC (US) 4,968,716 A 11/1990 Markham 4,975,272 A 12/1990 Voyt 5,021,452 A 6, 1991 Labbé (*) Notice: Subject to any disclaimer, the term of this 5,070,085 A 12/1991 Markham patent is extended or adjusted under 35 5,078,129 A 1/1992 Kleinberg et al. U.S.C. 154(b) by 0 days. 5,238,683 A 8/1993 Crystal 5,281, 196 A 1/1994 SultenfuSS 5,304,724 A 4, 1994 Newton (21) Appl. No.: 14/446,192 5,612.208 A 3, 1997 Nakanishi et al. 5,626,883. A 5, 1997 Paul 5,824,693. A 10/1998 Goldberg (22) Filed: Jul. 29, 2014 5,869,116 A 2, 1999 Yoo 5,876,700 A 3/1999 Boucher, Jr. et al. (65) Prior Publication Data 5,989,521 A 1 1/1999 Crystal 6,228,347 B1 5, 2001. Hersh US 2015/OO 10654 A1 Jan. 8, 2015 6,492,328 B2 12/2002 Lehrer et al. 6,495,170 B1 12/2002 Smit et al. 6,603,012 B2 8, 2003 Belloni et al. 6,655,385 B1 12/2003 Curti et al. Related U.S. Application Data 6,705,316 B2 3/2004 Blythe et al. 6,723,703 B2 4/2004 Gaston et al. (63) Continuation of application No. 7,129,035 B2 10/2006 Goldstein et al. PCT/US2013/067307, filed on Oct. 29, 2013. 7,179,791 B2 2/2007 Stamler et al. 7,572,251 B1 8, 2009 Davison et al. (60) Provisional application No. 61/719,804, filed on Oct. 7,591,999 B2 9/2009 Matsuyama et al. 29, 2012. (Continued) (51) Int. Cl. FOREIGN PATENT DOCUMENTS A6 IK38/00 (2006.01) AU 200231.0351 A1 12/2002 A6 IK38/06 (2006.01) AU 20O2345757 A1 12/2002 A6 IK3I/98 (2006.01) A 6LX3L/375 (2006.01) (Continued) A6 IK 45/06 (2006.01) A6 IK33/10 (2006.01) OTHER PUBLICATIONS A6 IK9/00 (2006.01) A6 IK38/40 (2006.01) Fitzpatrick et al. Glutathione Oxidation is Associated With Airway A6 IK38/44 (2006.01) Macrophage Functional Impairment in Children With Severe AOIN I/02 (2006.01) Asthma, Pediatr Res. Feb. 2011; 69(2): 154-159.* A6 IK33/00 (2006.01) (Continued) (52) U.S. Cl. CPC ............ A6 IK38/063 (2013.01); A0IN I/0226 (2013.01); A61 K9/006 (2013.01); A61 K9/008 Primary Examiner — Karlheinz, R Skowronek (2013.01); A61 K9/0031 (2013.01); A61 K Assistant Examiner — Sergio Coffa 9/0034 (2013.01); A61 K9/0075 (2013.01); A6 IK3I/198 (2013.01); A61 K3I/375 (74) Attorney, Agent, or Firm — Myers Bigel & Sibley, P.A. (2013.01); A61 K33/00 (2013.01); A61 K33/10 (2013.01); A61 K38/40 (2013.01); A61 K 38/443 (2013.01); A61K 45/06 (2013.01); C12Y (57) ABSTRACT 101/03004 (2013.01); C12Y III/01007 The present invention provides compositions and formula (2013.01); C12Y302/01011 (2013.01); C12Y tions comprising glutathione with or without thiocyanate and 302/01017 (2013.01); C12Y302/01059 methods of use thereof to treat diseases and disorders in (2013.01) mucosal/epithelial tissue. (58) Field of Classification Search None See application file for complete search history. 26 Claims, 11 Drawing Sheets US 9,308.234 B2 Page 2 (56) References Cited CN 101.491495 B 6, 2012 CN 101.384288 B 9, 2012 U.S. PATENT DOCUMENTS CN 1021009004 B 4/2013 DE 2845484 A1 4, 1980 7,790,762 B2 9/2010 Day et al. DE 1993.5763 A1 2/2001 8,022,082 B2 9/2011 Zierenberg DE 102004.035113 A1 2/2006 8,067,441 B2 11/2011 Gil et al. DE 60212837 T2 6, 2007 8,202,525 B2 6/2012 Crain et al. DE 2120.1110.0034 U1 7, 2012 8,211,628 B2 7/2012 Thatte et al. EP O 326 826 A1 8, 1989 8,217,006 B2 7/2012 Stamler et al. EP O 494405 A2 7, 1992 8,217,033 B2 7/2012 Gizurarson EP O 494405 B1 10, 1996 8,221.329 B2 7/2012 Hartings et al. EP O 494405 B2 4, 2000 8,267,084 B2 9/2012 Kwok EP 1 250 143 A2 10, 2002 8,327,843 B2 12/2012 Warden et al. EP O 938 331 B1 12/2002 2003/0082101 A1 5/2003 Taylor et al. EP 1282 416 A2 2/2003 2003. O1352O1 A1 7, 2003 Gonnelli EP 1569 511 A1 9, 2005 2003/0183226 A1 10, 2003 Brand et al. EP 1809 101 A2 5, 2006 2004/0209235 A1 10, 2004 Goldstein et al. EP 1701 732 A2 9, 2006 2004/022O262 A1 11/2004 Hsu et al. EP 1706 O25 A1 10, 2006 2004/0229815 A1 1 1/2004 Nagasawa et al. EP 1711 273 A1 10/2006 2005/0022806 A1 2/2005 Beaumont et al. EP 1996 159 A2 12/2008 2006/0204557 A1 9/2006 Gupta EP 1474 158 B1 10/2009 2006/0228693 A1 10, 2006 SO11 EP 2 139 465 A1 1/2010 2006/0258599 A1 11, 2006 Childers EP 1333 823 B1 3f2010 2007/0027375 A1 2/2007 Melker et al. EP 2189 153 A2 5, 2010 2007/0049641 A1 3f2007 Tirouvainziam et al. EP 2274 619 A2 1/2011 2007/0181444 A1 8/2007 Bernstein et al. EP 2 349 428 A1 8, 2011 2008/O187901 A1 8/2008 Doorschodt et al. EP 2444 121 A1 4, 2012 2009/0010912 A1 1/2009 Brands et al. EP 1909 912 B1 6, 2012 2009/0092559 A1 4, 2009 Hoelz et al. EP 1817 OO6 B1 9, 2012 2009/0145441 A1 6/2009 Doshi et al. EP 2 139 465 B1 9, 2012 2009/0326861 Al 12/2009 Langford et al. EP 2525 777 A2 11/2012 2010.0065048 A1 3/2010 Mueller-Walz et al. 206.43 3.36. 2010/0233295 A1 9/2010 Gupta et al. JP 2008519830 6, 2008 2011/001 1889 A1 1/2011 Bonney et al. JP 2009528372 8, 2009 2011/O159048 A1 6, 2011 Crain et al. JP 4652664 B2 3, 2011 2011/01781.52 A1 7, 2011 Savion et al. MX 2008O11187 12/2008 2011/0290256 A1 12/2011 Sather et al. MX 2009001855 3, 2009 2012, 0021071 A1 1/2012 Bordeau et al. SG 170063 A1 4/2011 2012/004.8271 A1 3/2012 O'Donnell et al. WO WO 97.31620 9, 1997 2012fO165596 A1 6, 2012 Schmidt WO WO98, 19694 5, 1998 2012/0171239 A1 7, 2012 Mizel WO WO99.52560 10, 1999 2012, 0215278 A1 8, 2012 Penner WO WOO1? 15692 A1 3f2001 2012fO264103 A1 10, 2012 Thatte et al. WO WOO1/3783O A1 5, 2001 2012/0282591 A1 11/2012 Thatte et al. WO WOO1,80937 A1 11, 2001 2012fO29 1780 A1 11/2012 Donovan et al. WO WOO1,89520 A2 11/2001 2012fO294822 A1 11/2012 Russo et al. WO WOO1,89520 A3 11, 2001 WO WOO2,32418 A1 4, 2002 WO WO O2/O55O18 A2 7, 2002 FOREIGN PATENT DOCUMENTS WO WO O2/O55O18 A3 T 2002 WO WO O2/100478 A2 12/2002 AU 2003302898 A1 6, 2004 WO WO O2/100478 A3 12/2002 AU 20043.15267 A1 8/2005 WO WO 2004/052098 A1 6, 2004 AU 2005302851 A1 5, 2006 WO WO 2004/078211 A1 9, 2004 AU 2007224,123 A1 2/2007 WO WO 2005, O74903 A2 8, 2005 AU 20043.15267 B2 1/2009 WO WO 2005, O74903 A3 8, 2005 AU 2009205945 A1 T 2009 WO WO 2005/120457 A1 12/2005 AU 2005.305456 B2 5, 2011 WO WO 2006/052133 A2 5, 2006 AU 2011224102 A1 10, 2011 WO WO 2006/052133 A3 5, 2006 AU 2005302851 B2 2/2012 WO WO 2006/0543O4 A2 5, 2006 AU 20122O1954 A1 4, 2012 WO WO 2006/060120 A2 6, 2006 CA 2O58793 A1 T 1992 WO WO 2006/060120 A3 6, 2006 CA 26.20123 A1 3f2007 WO WO 2006/064271 A1 6, 2006 CA 2644096 A1 9, 2007 WO WO 2006/1293O4 A3 12/2006 CA 2673478 A1 T 2008 WO WO 2007/017146 A2 2/2007 CA 278.505.6 A1 T 2011 WO WO 2007/024876 A2 3, 2007 CA 2790337 A1 8, 2011 WO WO 2007/024876 A3 3.2007 CA 26.20123 C 11 2011 WO WO 2007/103194 A2 9, 2007 N Se: A 93.93 WO WO 2007/103194 A3 9, 2007 CN 101.098622 A 1, 2008 WO WO 2007.1341.80 A2 11/2007 CN 101.313293.
Load more

Recommended publications
  • Screening of Clinically Approved and Investigation
    Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor- Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study Serdar Durdagi1,*, Busecan Aksoydan1,2, Berna Dogan1, Kader Sahin1, Aida Shahraki1,3, Necla Birgul-Iyison3 1Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, Istanbul, Turkey 2Neuroscience Program, Graduate School of Health Sciences, Bahçeşehir University, Istanbul, Turkey 3Department of Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey Abstract There is an urgent need for new drugs against COVID-19. Since designing a new drug and testing its pharmacokinetics and pharmacodynamics properties may take years, here we used a physics-driven high throughput virtual screening drug re-purposing approach to identify new compounds against COVID- 19. As the molecules considered in repurposing studies passed through several stages and have well- defined profiles, they would not require prolonged pre-clinical studies and hence, they would be excellent candidates in the cases of disease emergencies or outbreaks. While the Spike Protein is the key for the virus to enter the cell through the interaction with ACE2, enzymes such as main protease are crucial for the life cycle of the virus. These proteins are the most attractive targets for the development of new drugs against COVID-19 due to their pivotal roles in the fusion, replication and transcription of the virus. We used 7922 FDA approved small molecule drugs as well as compounds in clinical investigation from NIH Chemical Genomics Center (NCGC) Pharmaceutical Collection (NPC) database in our drug repurposing study.
    [Show full text]
  • Screening of Clinically Approved and Investigation Drugs As Potential
    Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study Serdar Durdagi1,*, Busecan Aksoydan1,2, Berna Dogan1, Kader Sahin1, Aida Shahraki1,3 1Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, Istanbul, Turkey 2Neuroscience Program, Graduate School of Health Sciences, Bahçeşehir University, Istanbul, Turkey 3Department of Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey Abstract There is an urgent need for a new drug against COVID-19. Since designing a new drug and testing its pharmacokinetics and pharmacodynamics properties may take years, here we used a physics-driven high throughput virtual screening drug re-purposing approach to identify new compounds against COVID-19. As the molecules considered in repurposing studies passed through several stages and have well-defined profiles, they would not require prolonged pre- clinical studies and hence, they would be excellent candidates in the cases of disease emergencies or outbreaks. While the spike protein is the key for the virus to enter the cell though the interaction with ACE2, enzymes such as main protease are crucial for the life cycle of the virus. This protein is one of the most attractive targets for the development of new drugs against COVID-19 due to its pivotal role in the replication and transcription of the virus. We used 7922 FDA approved small molecule drugs as well as compounds in clinical investigation from NIH Chemical Genomics Center (NCGC) Pharmaceutical Collection (NPC) database in our drug repurposing study. Both apo and holo forms of target protein COVID-19 main proteases were used in virtual screening.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • WO 2014/184553 Al 20 November 2014 (20.11.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/184553 Al 20 November 2014 (20.11.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/34 (2006.01) A61K 31/535 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/427 (2006.01) A61P 31/18 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/513 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/GB20 14/05 1478 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 14 May 2014 (14.05.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1749/MUM/2013 15 May 2013 (15.05.2013) IN kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: CIPLA LIMITED [—/IN]; Cipla House, Pen UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, insula Business Park, Ganpatrao Kadam Marg, Lower TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Parel, Mumbai-400 013 (IN).
    [Show full text]
  • Anti-Viral Nucleoside Analogs and Methods for Treating Viral Infections, Especially Hiv Infections
    (19) & (11) EP 2 298 783 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.03.2011 Bulletin 2011/12 C07H 19/10 (2006.01) A61K 31/7068 (2006.01) A61P 31/18 (2006.01) (21) Application number: 10155533.2 (22) Date of filing: 18.02.2004 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Cheng, Yung-Chi HU IE IT LI LU MC NL PT RO SE SI SK TR WOODBRIDGE, CT 06525 (US) Designated Extension States: • Tanaka, Hiromichi AL LT LV MK YOKOHAMA 224-0028 (JP) • Baba, Masanori (30) Priority: 19.03.2003 US 448554 KAGOSHIMA Fukuoka 891-0103 (JP) (62) Document number(s) of the earlier application(s) in (74) Representative: Dall’Olio, Giancarlo et al accordance with Art. 76 EPC: Invention S.r.l. 04775776.0 / 1 653 976 Via delle Armi 1 40137 Bologna (IT) (71) Applicants: • Yale University Remarks: New Haven, CT 06511 (US) This application was filed on 04-03-2010 as a • Cheng, Yung-Chi divisional application to the application mentioned Woodbridge, CT 06525 (US) under INID code 62. • Tanaka, Hiromichi Yokohama 224-0028 (JP) (54) Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections (57) The present invention relates to novel com- n-C≡C-Ra, Formula (XII) or Formula (XIII) with the pro- pounds according to the general Formulae (I, II, III, IV or viso that R4 and R5 are not both H; Ra is H,F,Cl,Br,I or V); wherein B is nucleoside base according to the struc- -C1-C4 alkyl, preferably H or CH3; Y is H, F, C1, Br, I or ture Formula (VI); R is H, F, Cl, Br, I, C1-C4 alkyl (pref- -C1-C4 alkyl, preferably H or CH3; and n is 0,1,2,3,4 or erably CH3), -C≡N, -C≡C-Ra, Formula (VII); X is H, C 1-C4 5, preferably 0, 1 or 2; and their anomers, pharmaceuti- alkyl (preferably CH 3), F,Cl,Br or 1; Z is 0 or CH 2 with the cally acceptable salts, solvates or polymorphs thereof.
    [Show full text]
  • Repurposing of FDA Approved Drugs
    Antiviral Drugs (In Phase IV) ABACAVIR GEMCITABINE ABACAVIR SULFATE GEMCITABINE HYDROCHLORIDE ACYCLOVIR GLECAPREVIR ACYCLOVIR SODIUM GRAZOPREVIR ADEFOVIR DIPIVOXIL IDOXURIDINE AMANTADINE IMIQUIMOD AMANTADINE HYDROCHLORIDE INDINAVIR AMPRENAVIR INDINAVIR SULFATE ATAZANAVIR LAMIVUDINE ATAZANAVIR SULFATE LEDIPASVIR BALOXAVIR MARBOXIL LETERMOVIR BICTEGRAVIR LOPINAVIR BICTEGRAVIR SODIUM MARAVIROC BOCEPREVIR MEMANTINE CAPECITABINE MEMANTINE HYDROCHLORIDE CARBARIL NELFINAVIR CIDOFOVIR NELFINAVIR MESYLATE CYTARABINE NEVIRAPINE DACLATASVIR OMBITASVIR DACLATASVIR DIHYDROCHLORIDE OSELTAMIVIR DARUNAVIR OSELTAMIVIR PHOSPHATE DARUNAVIR ETHANOLATE PARITAPREVIR DASABUVIR PENCICLOVIR DASABUVIR SODIUM PERAMIVIR DECITABINE PERAMIVIR DELAVIRDINE PIBRENTASVIR DELAVIRDINE MESYLATE PODOFILOX DIDANOSINE RALTEGRAVIR DOCOSANOL RALTEGRAVIR POTASSIUM DOLUTEGRAVIR RIBAVIRIN DOLUTEGRAVIR SODIUM RILPIVIRINE DORAVIRINE RILPIVIRINE HYDROCHLORIDE EFAVIRENZ RIMANTADINE ELBASVIR RIMANTADINE HYDROCHLORIDE ELVITEGRAVIR RITONAVIR EMTRICITABINE SAQUINAVIR ENTECAVIR SAQUINAVIR MESYLATE ETRAVIRINE SIMEPREVIR FAMCICLOVIR SIMEPREVIR SODIUM FLOXURIDINE SOFOSBUVIR FOSAMPRENAVIR SORIVUDINE FOSAMPRENAVIR CALCIUM STAVUDINE FOSCARNET TECOVIRIMAT FOSCARNET SODIUM TELBIVUDINE GANCICLOVIR TENOFOVIR ALAFENAMIDE GANCICLOVIR SODIUM TENOFOVIR ALAFENAMIDE FUMARATE TIPRANAVIR VELPATASVIR TRIFLURIDINE VIDARABINE VALACYCLOVIR VOXILAPREVIR VALACYCLOVIR HYDROCHLORIDE ZALCITABINE VALGANCICLOVIR ZANAMIVIR VALGANCICLOVIR HYDROCHLORIDE ZIDOVUDINE Antiviral Drugs (In Phase III) ADEFOVIR LANINAMIVIR OCTANOATE
    [Show full text]
  • WO 2013/167743 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/167743 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/18 (2006.01) A61K 31/708 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/522 (2006.01) A61K 45/06 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/675 (2006.01) A61P 29/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 31/7068 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (21) International Application Number: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, PCT/EP2013/059752 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (22) International Filing Date: TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 10 May 2013 (10.05.2013) ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 12167771 .0 11 May 2012 ( 11.05.2012) EP TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: AKRON MOLECULES GMBH [AT/AT]; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Helmut-Qualtinger-Gasse 2, A-1030 Vienna (AT).
    [Show full text]
  • Providing for Duty-Free Treatment for Specified Pharmaceutical Active
    COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 12.02.1999 COM(1999)2 final Proposal for a COUNCIL Rl;_GULATION (EC) providing for duty-free treatment for specified pharmaceutical active ingredients bearing an international non-proprietary name (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceutical products (presented by the Commission) EXPLANATORY MEMORANDUM I. Pursuant to the conclusions r~.:ached in Uruguay Round Record of Discussions (L/4740 of 25 March 1994) on duty-free treatment for pharmaceutical products, the Commission has participated in the second review of the product coverage to include, r by consensus, additional products for duty-free treatment. 2. The outcome of the review is that 272 pharmaceutical active ingredients bearing an "international nonproprietary name" (INN) from the World Health Organisation and 363 products used for the manufacture of finished pharmaceuticals should be added to the list of products already receiving duty-free treatment and also that the list of specified prefixes and suffixes for salts and esters of INNs should be expanded by five names. 3. The Commission proposes in line with other countries granting duty-free treatment for these additional products that the duty-free treatment shall commence from 1 July 1999. 4. For these reasons the Commission proposes that the Council adopt the Regulation contained in the Annex to this Communication. · jt II I il,, i ·'1.· i. 2 Proposal for a COUNCIL REGULATION (EC) providing for duty-free
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • WHO Drug Information Vol. 11, No. 3, 1997
    WHO DRUG INFORMATION VOLUME 11- NUMBER 3 • 1997 RECOMMENDED INN LIST 38 INTERNATIONAL NONPROPRIETARY N A M E S F O R P H A R M A C E U T I C A L SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 11, Number 3, 1997 World Health Organization, Geneva WHO Drug Information Contents Essential Drugs WHO Model Formulary Antiprotozoal drugs General Policy Issues Drugs used in amoebiasis 144 The dangers of counterfeit and substandard Diloxanide 144 active pharmaceutical ingredients 123 Drugs used in giardiasis Metronidazole 145 Drugs used in leishmaniasis 145 Quality Assurance Issues Meglumine antimoniate & The importance of analytical procedures sodium stibogluconate 146 in regulatory control 128 Pentamidine 147 Amphotericin B 148 Drugs used in trypanosomiasis 148 Reports on Individual Drugs Melarsoprol 148 Simplified treatment for leprosy 131 Pentamidine 149 Should antibiotics be indicated for children Suramin sodium 149 with acute otitis media? 131 Eflornithine 151 Acetylsalicylic acid: confirmed efficacy Drugs used in American trypanosomiasis 151 after stroke 132 Benznidazole 151 Antiretroviral therapy for HIV: latest guidelines 134 Nifurtimox 152 General Information ATC/DDD Classification Biological standardization: report of the 153 Expert Committee 138 (temporary) Recent Publications and Documents Regulatory Matters Drugs for the elderly 155 Irinotecan-associated mortality 141 Rapid examination methods against counterfeit HIV protease inhibitors associated with and substandard drugs 155 diabetes 141 Countering counterfeiting 155 Valvular
    [Show full text]
  • Piperidine Derivatives Useful As Ccr5
    Europäisches Patentamt & (19) European Patent Office Office européen des brevets (11) EP 1 421 075 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 401/04 (2006.01) A61P 31/18 (2006.01) 07.06.2006 Bulletin 2006/23 A61K 31/435 (2006.01) (21) Application number: 02766142.0 (86) International application number: PCT/US2002/027389 (22) Date of filing: 28.08.2002 (87) International publication number: WO 2003/020716 (13.03.2003 Gazette 2003/11) (54) PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS FOR THE TREATMENT OF HIV PIPERIDIN DERIVATE ALS CCR5 REZEPTOR ANTAGONISTEN ZUR BEHANDLUNG VON HIV DERIVES DE LA PIPERIDINE UTILISES COMME ANTAGONISTES DU CCR5 POUR LE TRAITEMENT DU SIDA (84) Designated Contracting States: (74) Representative: Adams, Harvey Vaughan John et AT BE BG CH CY CZ DE DK EE ES FI FR GB GR al IE IT LI LU MC NL PT SE SK TR Mathys & Squire Designated Extension States: 120 Holborn AL LT LV MK RO SI London EC1N 2SQ (GB) (30) Priority: 29.08.2001 US 315683 P (56) References cited: EP-A- 0 151 824 EP-A- 0 855 999 (43) Date of publication of application: WO-A-01/30348 WO-A-01/77101 26.05.2004 Bulletin 2004/22 WO-A-97/24324 WO-A-98/01425 WO-A-02/081449 US-A- 5 952 349 (73) Proprietor: SCHERING CORPORATION Kenilworth, NJ 07033-0530 (US) • PALANI, A. ET AL.: "Discovery of 4-[(Z)-(4- Bromophenyl)-(ethoxyimino)methyl ]-1’-[(2,4- (72) Inventors: dimethyl-3-pyridinyl)carbonyl]- 4’-methyl-1,4’- • PALANI, Anandan bipiperidine N-Oxide (SCH 351125): An Orally Bridgewater, NJ 08807 (US) Bioavailable Human CCR5 Antagonist for the • MILLER, Michael, W.
    [Show full text]